Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations
Glioblastoma (GBM) is the most aggressive tumor type whose resistance to conventional treatment is mediated, in part, by the angiogenic process. New treatments involving the application of nanoformulations composed of encapsulated drugs coupled to peptide motifs that direct drugs to specific targets...
Main Authors: | Gabriel Nery de Albuquerque Rego, Arielly da Hora Alves, Mariana Penteado Nucci, Javier Bustamante Mamani, Fernando Anselmo de Oliveira, Lionel Fernel Gamarra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/12/4490 |
Similar Items
-
Anti-Invasion and Antiangiogenic Effects of Stellettin B through Inhibition of the Akt/Girdin Signaling Pathway and VEGF in Glioblastoma Cells
by: Shu-Yu Cheng, et al.
Published: (2019-02-01) -
SapC-DOPS Nanotherapy for the Treatment of Glioblastoma
by: Wojton, Jeffrey Alan, Jr.
Published: (2014) -
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
by: Wei Li, et al.
Published: (2020-12-01) -
Apelin Controls Angiogenesis-Dependent Glioblastoma Growth
by: Anne Frisch, et al.
Published: (2020-06-01) -
New perspectives in glioblastoma antiangiogenic therapy
by: Alisa Madalina Popescu, et al.
Published: (2015-12-01)